RedHill Biopharma Ltd. Sponsored ADR Aktie News

The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's strong global intellectual property portfolio across multiple indications -- U.S. Army studies suggest that opaganib may be the first host-directed molecule to show activity in vivo in Ebola virus disease, delivering ...

First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1  for early COVID-19 outpatient treatment, funded through non-dilutive external sources, including the U.S. Department of Defense The study is expected to be completed by the end of 2024 RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising eff...

RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base   Focused externally funded R&D: Opaganib for nuclear and chemical medical countermeasure (NIH funding):  Selected for evaluation by two U.S. government countermeasures programs for Acute Radiation Syndrome (ARS) and Sulfur Mu...

TEL AVIV, Israel and RALEIGH, N.C. , April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia 1  as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia protection until February 12, 2034 This new patent adds to the existing strong intellectual property portfolio protecting Talicia, including composition of matter and other patents and FDA-granted data exclusivities granted under the GA...

The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by ASPR/BARDA and NIH/NIAID, in collaboration with Battelle[1], have selected opaganib for evaluation as a potential medical countermeasure (MCM) against Sulfur Mustard exposure Opaganib, a novel oral small molecule, is the first sphingosine kinase...

The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation  Opaganib is the first selective sphingosine kinase-2 ( SPHK2) inhibitor investigational drug targeting sphingolipid metabolism for the treatment of radiation-induced inflammation O...

TEL AVIV, Israel and RALEIGH, N.C., Jan. 26, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.